Risk of second cancers in Waldenström macroglobulinemia

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 411-415

  Varettoni, M ^a   Tedeschi, A ^b   Arcaini, L ^a   Pascutto, C ^a   Vismara, E ^b   Orlandi, E ^a   Ricci, F ^b   Corso, A ^a   Greco, A ^b   Mangiacavalli, S ^a   Lazzarino, M ^a   Morra, E ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Hematologic malignancies; Second cancers; Solid tumors; Waldenstr m macroglobulinemia

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; FLUDARABINE; MONOCLONAL ANTIBODY; NUCLEOSIDE DERIVATIVE; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BRAIN CANCER; CANCER INCIDENCE; CANCER RISK; FACTORIAL ANALYSIS; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SECOND CANCER; SOLID TUMOR; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RISK FACTORS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84856362228     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr119     Document Type: Article

References (21)

1. Travis LB, Curtis RE, Glimelius B et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993; 85: 1932-1937.
2. Brennan P, Scelo G, Hemminki K et al. Second primary cancers among 109000 cases of non-Hodgkin's lymphoma. Br J Cancer 2005; 93: 159-166.
3. Tward JD, Wendland MM, Shrieve DC et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006; 107(1): 108-115.
4. Mudie NY, Swerdlow AJ, Higgins CD et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British cohort study. J Clin Oncol 2006; 24(10): 1568-1574.
5. Sacchi S, Marcheselli L, Bari A et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93(3): 398-404.
6. Travis LB, Curtis RE, Hankey BF et al. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1992; 84: 1422-1427.
7. Tsimberidou AM, Wen S, McLaughlin P et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2009; 27(6): 904-910.
8. Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and causespecific mortality among 3104 patients with hairy cell leukemia: a populationbased study. J Natl Cancer Inst 2007; 99: 215-222.
9. Greene MH, Hoover RN, Fraumeni JF Jr. Subsequent cancers in patients with chronic lymphocytic leukaemia: a possible immunologic mechanism. J Natl Cancer Inst 1978; 61: 337-340.
10. Cheson BD, Vena DA, Barrett J et al. Second malignancies as a consequence of nucleoside analogs therapy for chronic lymphocytic leukaemias. J Clin Oncol 1999; 17: 2454-2460.
11. Thornton PD, Bellas C, Santon A et al. Richter's transformation of chronic lymphocytic leukaemia: the possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. Leuk Res 2005; 29: 389-395.
12. LeBlond V, Ben-Othman T, Deconinck E et al. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Cooperatif Macroglobulinemie. J Clin Oncol 1998; 16: 2060-2064.
13. Leblond V, Levy V, Maloisel F et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood 2001; 98: 2640-2644.
14. Tamburini J, Levy V, Chaleteix C et al. Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients. Leukemia 2005; 19: 1831-1834.
15. Treon SP, Branagan AR, Ioakimidis L et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 2009; 113(16): 3673-3678.
16. Leleu X, Soumerai J, Roccaro A et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009; 27(2): 250-255.
17. Owen RG, Treon SP, Al-Katib A et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003; 30: 110-115.
18. Garcia-Sanz Montoto S, Torrequebrada A, de Coca AG et al. Spanish Group for the Study of Waldenström Macroglobulinaemia and PETHEMA (Programme for the Study and Treatment of Haematological Malignancies). Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115(3): 575-582.
19. Facon T, Brouillard M, Duhamel A et al. Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 11(8): 1553-1558.
20. Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence and therapeutic strategies. Cancer 2005; 103: 216-228.
21. Hunter ZR, Manning RJ, Hanzis C et al. IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. Haematologica 2010; 95(3): 470-474.